Acrivon Therapeutics, Inc. ( (ACRV) ) has shared an announcement.
Acrivon Therapeutics has shared promising Phase 2 data for ACR-368, showing a 62.5% response rate in endometrial cancer patients selected by their OncoSignature assay, with responders still in treatment and no median duration of response reached at approximately 6 months. Additionally, the FDA has cleared their next drug candidate, ACR-2316, for Phase 1 trials, with dosing to start in Q4 2024. The Company’s financials are solid, with sufficient funds to operate until the second half of 2026, and their proprietary AP3 Interactome platform continues to drive their precision medicine approach.
For detailed information about ACRV stock, go to TipRanks’ Stock Analysis page.
